Anti-CD30 Antibody-Drug Conjugates for Relapsed DLBCL
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diffuse large B-cell lymphoma (DLBCL), particularly in relapsed or refractory cases, have limited efficacy and significantly impact patients' quality of life, with poor long-term survival rates and limited response to salvage chemotherapy and autologous stem cell transplant.
Innovation Solution
The use of lenalidomide in combination with anti-CD30 antibody-drug conjugates, such as brentuximab vedotin, and anti-CD20 antibodies like rituximab, to target and deplete cancer cells, offering a novel therapeutic approach for advanced and relapsed DLBCL stages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemoimmunotherapy (R-CHOP) is used for DLBCL treatment, then initial cure rate is achieved, but quality of life deteriorates and long-term survival remains poor for relapsed cases
Solution Approach 1:
The treatment approach is segmented into distinct phases: initial R-CHOP therapy for curative intent, followed by alternative strategies (brentuximab vedotin, lenalidomide, or CAR-T) for relapsed/refractory cases. This segmentation allows optimization of quality of life in the relapse phase without compromising initial cure rates.
2Reliability
If salvage chemotherapy is administered to relapsed patients, then some response is achieved, but response rate remains limited at 30-40%
Solution Approach 1:
The patent introduces novel therapeutic agents with different mechanisms of action (brentuximab vedotin targeting CD30, lenalidomide as an immunomodulator) to replace conventional salvage chemotherapy. This parameter change in drug mechanism achieves higher response rates (50-60% in brentuximab trials) while maintaining manageable treatment complexity.
3Reliability
If autologous stem cell transplant is performed, then long-term survival is improved for some patients, but 50% still relapse and treatment complexity increases
Solution Approach 1:
Brentuximab vedotin serves as an intermediary treatment between salvage chemotherapy and autologous stem cell transplant. By achieving higher response rates with brentuximab (50-60%) compared to salvage chemotherapy (30-40%), more patients become eligible for transplant, thereby improving long-term survival without increasing transplant complexity.
4Reliability
If combination therapy with brentuximab vedotin and lenalidomide is used, then objective response rate improves, but treatment complexity increases
Solution Approach 1:
The patent combines brentuximab vedotin (CD30-targeted ADC) with lenalidomide (immunomodulator) to create a synergistic combination therapy. Clinical trials demonstrated that this combination achieves objective response rates of 60-70% in relapsed/refractory DLBCL, overcoming the limitations of single-agent therapies while maintaining a manageable treatment protocol.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy demonstrates improved objective response rates, progression-free survival, and overall survival in patients with DLBCL, even in those who have received prior stem cell transplants or CAR-T therapy, providing a more effective treatment option for advanced and relapsed cases.
Implementation Method 1
Brentuximab vedotin is a CD30-directed antibody-drug conjugate (ADC) consisting of 3 components: 1) the chimeric IgG1 antibody cAC10, specific for human CD30
Implementation Method 2
Binding of MMAE to tubulin disrupts the microtubule network within the cell, subsequently inducing cell cycle arrest and apoptotic death of the cell
Data Source
AI summary
The invention provides anti-CD30 antibody-drug conjugates, such as brentuximab vedotin, and their use for the treatment of lymphoma, such as diffuse large B-cell lymphoma. The invention also provides the use of anti-CD30 antibody-drug conjugates, such as brentuximab vedotin, in combination with lenalidomide and/or anti-CD20 antibodies, such as rituximab, for the treatment of lymphoma, such as diffuse large B-cell lymphoma.